Renalytix announces a $30.0 million financing package
31 mars 2022 07h05 HE
|
Renalytix plc
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR...
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
31 mars 2022 07h00 HE
|
Renalytix plc
LONDON and SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing...
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
30 mars 2022 07h00 HE
|
Renalytix plc
NEW YORK and SALT LAKE CITY, March 30, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced that, following the Company’s announcement on February 22, 2022, Timothy...
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
29 mars 2022 07h00 HE
|
Renalytix plc
NEW YORK and SALT LAKE CITY, March 29, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the proprietary Renalytix Accelerating Precision medicine In Diabetes (RAPID)...
Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31
25 mars 2022 07h00 HE
|
Renalytix plc
NEW YORK and SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release its second quarter and first half fiscal year 2022...
Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform
09 mars 2022 07h00 HE
|
Renalytix plc
NEW YORK and SALT LAKE CITY, March 09, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the launch of its new provider access portal, myIntelX, which will provide...
KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care
24 févr. 2022 07h00 HE
|
Renalytix plc
NEW YORK and SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the presentation of new clinical data for KidneyIntelX™ bioprognostic™ testing...
Renalytix to Present at Cowen 42nd Annual Health Care Conference
22 févr. 2022 07h30 HE
|
Renalytix plc
NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming...
Renalytix to Appoint Timothy Scannell to Board of Directors
22 févr. 2022 07h00 HE
|
Renalytix plc
NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its intention to appoint Timothy Scannell to its board of directors as an...
Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
27 janv. 2022 07h00 HE
|
Renalytix plc
NEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming...